Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 68 Publications

11 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NE[3dYpEgXSxdH;4bYMhSXO|YYm= NHq3Zoc1QCCq MlzLSG1UVw>? MkOyR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?= MlLVNlE2PzJ3OEm=
BAF3 MW\DfZRwfG:6aXOgRZN{[Xl? MnnMOFghcA>? NXe0WnJtTE2VTx?= MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIFyxNVk3VSCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIEKuNkDPxE1? NHXTeJEzOTV5MkW4PS=>
BAF3 NF\jOHNEgXSxdH;4bYMhSXO|YYm= NUe4[IVuPDhiaB?= NYW4U2VYTE2VTx?= MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshf2m2aDDJR|UxKG:oIECuNlgh|ryP M4joTFIyPTd{NUi5
Kelly MVjDfZRwfG:6aXOgRZN{[Xl? MUnEUXNQ NHjnWW9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBM\WyueTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjR{IN88US=> NGm4S5gzOTV5MkW4PS=>
SH-SY5Y NFvHN5NEgXSxdH;4bYMhSXO|YYm= NV7Cb3lKTE2VTx?= M{nxSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC53MzFOwG0> NWjnd|hFOjF3N{K1PFk>
SMS-KCN MUjDfZRwfG:6aXOgRZN{[Xl? NYT0VHVQTE2VTx?= NVLrR5VlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW02VLVvDUkBk\WyuczDlfJBz\XO|aX7nJGFNUyCUMUK3OXEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkmxJO69VQ>? NV7GUlBFOjF3N{K1PFk>
BAF3 Mlj5R5l1d3SxeHnjJGF{e2G7 NGHFeFc1QCCq M{fVN2ROW09? MlfOR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3BUGshf2m2aDDJR|UxKG:oIECuNVkh|ryP MUOyNVU4OjV6OR?=
3T3 NGi5RZNHfW6ldHnvckBCe3OjeR?= MVWxJIg> MYTEUXNQ MUXJcohq[mm2aX;uJI9nKFKRTjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yODFOwG0> MmHiNlE5OTJ2MUS=
3T3-E NWe1XVNZTnWwY4Tpc44hSXO|YYm= MkPyNUBp NHTSZWpFVVOR M2rJbmlvcGmkaYTpc44hd2ZiVFnFNkBie3Onc4Pl[EBoem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC52NEig{txO MYOyNVgyOjRzNB?=
A549 MnLIT4lv[XOnIFHzd4F6 MX[xJIg> MoDQSG1UVw>? MkTiTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCClLV3FWEBscW6jc3Wg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTGdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODhizszN M1PEZVIyQDF{NEG0
BAF3-BCL NEPiT|FHfW6ldHnvckBCe3OjeR?= NF3x[5QyKGh? NW\aWGNGTE2VTx?= M{XNS2lvcGmkaYTpc44hd2ZiQVLMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzLkG1PUDPxE1? M1nnZ|IyQDF{NEG0
HEK293 MkTwSpVv[3Srb36gRZN{[Xl? Ml\iNUBp NULxbXhPTE2VTx?= MX;Jcohq[mm2aX;uJI9nKEG[TDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5{OUSg{txO M{HSbVIyQDF{NEG0
HEK293 M4T4Z2Z2dmO2aX;uJGF{e2G7 MlXSNUBp NFTzUXpFVVOR Mn\4TY5pcWKrdHnvckBw\iCLUjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi56OEeg{txO MXyyNVgyOjRzNB?=
Jurkat M1LZTWZ2dmO2aX;uJGF{e2G7 MYexJIg> Ml\WSG1UVw>? M4TWcWlvcGmkaYTpc44hd2ZiTFPLJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lke0NUDPxE1? MoX1NlE5OTJ2MUS=
KARPAS299 NFKwfWpMcW6jc3WgRZN{[Xl? NGTKdIMyKGh? NGntUlBFVVOR MlzYTY5pcWKrdHnvckBw\iCDTFugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO Mnu2NlE5OTJ2MUS=
PAE MnXVSpVv[3Srb36gRZN{[Xl? NYP6VHZXOSCq MlqwSG1UVw>? MnvWTY5pcWKrdHnvckBw\iCWUlvCJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkO5PUDPxE1? NILQfpozOThzMkSxOC=>
BAF3 NHrOc4hHfW6ldHnvckBCe3OjeR?= NXLjd|loOi1|IHS= MmjwSG1UVw>? NYq0PFNsUW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgbY5{fWyrbjDy[YNmeHSxcjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDFwNkSzJO69VQ>? NEHsXJAzOzd2MkK1Ni=>
KARPAS299 NV7WbmFWS3m2b4TvfIlkKEG|c3H5 MXSyMVMh\A>? M2\EbGROW09? NYDZTlllUUN3ME2wMlA3PDJizszN MXGyN|c1OjJ3Mh?=
EBC1 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[3NkBp NWfvV|V1TE2VTx?= MojNTWM2OD1yLkCyN{DPxE1? MkHnNlM6QTN|Mki=
HCT116 MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXBO|IhcA>? NYjuVIVKTE2VTx?= NGLv[HdKSzVyPUG0MlgzKM7:TR?= NGXB[lczOzl7M{OyPC=>
MCF7 M2fwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXS3NkBp NW[4T5Q3TE2VTx?= Mm\zTWM2OD17LkW4JO69VQ>? MYSyN|k6OzN{OB?=
MDA-MB-231 NGnjc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjZPZJ6PzJiaB?= NF3tSHZFVVOR NXLQOllSUUN3ME2xNE45KM7:TR?= MmjGNlM6QTN|Mki=
MKN45 NH\TXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfSW4k4OiCq MYPEUXNQ NFLYNVhKSzVyPUCuNFE{KM7:TR?= MYSyN|k6OzN{OB?=
NCI-H441 Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\l[lczKGh? M1vpS2ROW09? NIfCN2lKSzVyPUG3MlI2KM7:TR?= NVr3UJV4OjN7OUOzNlg>
NCI-H661 NHzjNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXjbow4OiCq M2jtOWROW09? M3LWS2lEPTB;MUGuOFch|ryP M1fObFI{QTl|M{K4
SK-MEL-28 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrjdIV{PzJiaB?= MWfEUXNQ Mme4TWM2OD1zMD65O{DPxE1? M3PIOVI{QTl|M{K4
SKOV3 NVfjRoxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\ue|czKGh? NX3OeVd4TE2VTx?= MkPOTWM2OD1zMj64OUDPxE1? NILydlczOzl7M{OyPC=>
SNU5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[3NkBp MUDEUXNQ NYPneZI1UUN3ME2wMlAyPiEQvF2= NYHyVIk6OjN7OUOzNlg>
NCI-H2228 M2TmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYO3NkBp MlXmSG1UVw>? MYPJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4yOThizszN NYj4WnZROjR2M{K5NFk>
NCI-H3122 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7JO|IhcA>? MYnEUXNQ MlG5TY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTB6IN88US=> M1TabFI1PDN{OUC5
NCI-H3122 NHzzSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUm3NkBp M3TzNGROW09? NWDqSJBFUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshTzF{NknBJI12fGGwdDD3bZRpKEmFNUCgc4YhOC54MkOg{txO NFvwXGgzPDR|MkmwPS=>
NCI-H3122 Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXm3NkBp M33obGROW09? MWLJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= M13j[FI1PDN{OUC5
NIH-3T3 MXzLbY5ie2ViQYPzZZk> NX3SW4M3OSCq NUHkOlhRTE2VTx?= MkDsTY5pcWKrdHnvckBw\iCqdX3hckB4cWymIIT5dIUhTU2OND3meZNm\CCDTFug[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHXkJGFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? NI\lZYYzPDR|MkmwPS=>
NIH-3T3 MYTLbY5ie2ViQYPzZZk> NWnQTWJ{OSCq NGDBN5pFVVOR NI\uR3BKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjZ7QTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLk[wOUDPxE1? NV7XPXgyOjR2M{K5NFk>
NIH-3T3 NWrqbolGU2mwYYPlJGF{e2G7 MnXZNUBp MkP5SG1UVw>? M4LoU2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugV|EzOD[\IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNkK2JO69VQ>? MX6yOFQ{OjlyOR?=
NIH-3T3 NYnnOo1UU2mwYYPlJGF{e2G7 NVX6eW9WOSCq NVXqW2pZTE2VTx?= NFfSWVZKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLki0N{DPxE1? NW\kW5pEOjR2M{K5NFk>
NIH-3T3 M2Pt[2tqdmG|ZTDBd5NigQ>? MkjzNUBp M2P0XGROW09? NIn4O5BKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTV{UjDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iBzLkCyOkDPxE1? MnrxNlQ1OzJ7MEm=
BAF3 NIrjdllHfW6ldHnvckBCe3OjeR?= MUm3NkBp M1v1[WROW09? NEDWVlRKdmirYnn0bY9vKG:oIF7QUU9CVEtidILhcpNn\WO2ZXSgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yNUGg{txO MnzlNlQ1Pjh4M{K=
BAF3 M2fRVmN6fG:2b4jpZ{BCe3OjeR?= MkDmO|IhcA>? M1rISmROW09? NUXzbopJUUN3ME2wMlk5KM7:TR?= M3i4Z|I1PDZ6NkOy
NIH-3T3 MnPST4lv[XOnIFHzd4F6 NFG3VWcyKGh? NVHUV2M5UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BHOTF5NFygcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6xOlUh|ryP M3j5OFI1QDF7MUG2
NIH-3T3 MYrLbY5ie2ViQYPzZZk> NFLzW3QyKGh? Mn7VTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDDNVE2PllibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC52N{ig{txO MnPjNlQ5OTlzMU[=
NIH-3T3 NUHFcVhwU2mwYYPlJGF{e2G7 NHi2eHoyKGh? NGrZfJVKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjB{UjDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iBzLkG0PEDPxE1? MV6yOFgyQTFzNh?=
NIH-3T3 MY\LbY5ie2ViQYPzZZk> NVTFN2NiOSCq Mn\NTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzCxNVUyXGmwczDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iB|LkCzPUDPxE1? MkC2NlQ5OTlzMU[=
KARPAS299 NGrmOZpMcW6jc3WgRZN{[Xl? NWfvdVE5QTBibXnu MWfEUXNQ M4rFdGlvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{BxcG:|cHjvdplt[XSrb36g[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>? MlrkNlQ6ODB5NUC=
MKN 45 NFq5cZlMcW6jc3WgRZN{[Xl? M3rEVVEhcA>? MnH1SG1UVw>? M{nTVGlvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>? MoHWNlQ6ODB5NUC=
A549 MXvDfZRwfG:6aXOgRZN{[Xl? M4fWb|Q5KGh? NHXTNGtFVVOR MX3JR|UxKG:oIESuNFg1KM7:TR?= NV:5NY1HOjR7MEC4N|A>
NCI-H1975 MknSR5l1d3SxeHnjJGF{e2G7 MWe0PEBp NVjCXZY4TE2VTx?= MVjJR|UxKG:oIEeuOVUyKM7:TR?= MlfiNlQ6ODB6M{C=
NCI-H1993 NIXrRWdEgXSxdH;4bYMhSXO|YYm= Ml;MOFghcA>? Mlr3SG1UVw>? NFnjeJdKSzVyIH;mJFAvODZzIN88US=> MnnINlQ6ODB6M{C=
NCI-H1993 MV7BdI91d3OrczDBd5NigQ>? NH\XRWEyKM7:TR?= NFv0TpMzPCCq NVS0VFNGTE2VTx?= MlS0[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= Mm\uNlQ6ODB6M{C=
NIH-3T3 NHXJcHpEgXSxdH;4bYMhSXO|YYm= NEDtd4Q1QCCq NHnWXWRFVVOR NVnwRlI3UUN3MDDv[kAxNjN4NDFOwG0> M4LObFI1QTByOEOw
EBC1 NWTBe2xPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPsN4dtPzJiaB?= M3j0XGROW09? Mlm1TWM2OCCxZjCwMlAxPjlizszN NUPY[JdsOjR7MEC4N|E>
KARPAS299 NYDZbphyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jVWFczKGh? M4SxO2ROW09? NUjCWIhmUUN3MDDv[kAxNjJizszN M3zwUVI1QTByOEOx
NB1 NYLXfVZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn23TWM2OD17MT65PEBvVQ>? NI\scmZUSU6JRWK=
NCI-SNU-5 NWm5ZZF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO4TWM2OD1zMEWuO|Uhdk1? NF7wc3pUSU6JRWK=
SR MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLpTWM2OD1zMk[uN|Ehdk1? NInBSY1USU6JRWK=
SF539 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLlWVhKSzVyPUKwOE4zPCCwTR?= NEO2fFRUSU6JRWK=
SU-DHL-1 M1LORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPLTWM2OD1|M{[uPFIhdk1? NUOzUpNUW0GQR1XS
SCC-3 M4nzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEex[3JKSzVyPUO1Ok44PiCwTR?= MnzlV2FPT0WU
DEL M{HtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTN4OT65JI5O NHjNNpRUSU6JRWK=
CTV-1 NGXuV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTV7Nj60PEBvVQ>? MXTTRW5ITVJ?
EM-2 MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHjZ3FKSzVyPU[wNU4{PCCwTR?= MnjCV2FPT0WU
MHH-CALL-2 MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nlTWlEPTB;NkiyMlU4KG6P MmXWV2FPT0WU
KM12 NYHTeYNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTdyNj65JI5O MkK0V2FPT0WU
KINGS-1 NFvye5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTd2OT63OUBvVQ>? M2m1RnNCVkeHUh?=
MEG-01 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLS[4hKSzVyPUi1O{43PiCwTR?= MUTTRW5ITVJ?
BV-173 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPaZ49WUUN3ME2xMlA2QTl5IN88US=> NHnSeYFUSU6JRWK=
LAMA-84 MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjoTWM2OD1zLkO4NlgzKM7:TR?= NGW3XnpUSU6JRWK=
KARPAS-299 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[zbpJ7UUN3ME2xMlQxQDZzIN88US=> NV3OdVJUW0GQR1XS
K-562 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\OU2lEPTB;MT63NlI3QSEQvF2= MVjTRW5ITVJ?
SK-LMS-1 NH\E[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXmTWM2OD1zLke2PFY4KM7:TR?= MVnTRW5ITVJ?
MOLT-16 NG\pbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwOUW1O|Uh|ryP M2nJeXNCVkeHUh?=
CMK NIXqWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e2dGlEPTB;MT65OlE2QSEQvF2= NUPmTZNuW0GQR1XS
ST486 NVv3WZk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL3TWM2OD1{LkSzNFc{KM7:TR?= NUnTVpRFW0GQR1XS
CI-1 MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\sdFF1UUN3ME2yMlQ6PjV7IN88US=> MoWyV2FPT0WU
KP-N-RT-BM-1 NFTINFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwN{CxNlIh|ryP M1L5R3NCVkeHUh?=
ALL-PO M1\Vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTNwMUiyNFch|ryP MWHTRW5ITVJ?
KS-1 NH22fXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC5OZZzUUN3ME2zMlIyOjJ3IN88US=> NXf0Rmx7W0GQR1XS
Becker NVnGe2FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTRwMkO5N{DPxE1? NUn6fGZjW0GQR1XS
GDM-1 NGLFO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRwMkS2NVch|ryP M2i0bXNCVkeHUh?=
BC-1 NIDSXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDsTVhLUUN3ME20MlQ6Ojd5IN88US=> NFyzVGtUSU6JRWK=
NB14 MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWwTWM2OD12LkizOVI1KM7:TR?= MmT5V2FPT0WU
NOS-1 M4fJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rzU2lEPTB;NT6zN|g4PCEQvF2= M1y2VXNCVkeHUh?=
MZ1-PC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFewXYdKSzVyPUWuPFIyPTFizszN NV74RppHW0GQR1XS
A498 M4TjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPWNGtyUUN3ME22MlA5PDd|IN88US=> MU\TRW5ITVJ?
EW-16 NYfkTZg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPD[3lKSzVyPU[uN|c4PzNizszN MWnTRW5ITVJ?
NALM-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\DUGlEPTB;Nj62PFM5PyEQvF2= NX\mbZAzW0GQR1XS
EB-3 NFzMSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\XSmlEPTB;Nz6wO|I{OyEQvF2= MnfZV2FPT0WU
697 M16zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfyTWM2OD17LkK0N|I6KM7:TR?= MnzFV2FPT0WU
Ramos-2G6-4C10 NWjCXYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7SU5ByUUN3ME25MlU6QDR{IN88US=> M1\Zd3NCVkeHUh?=
KNS-81-FD M3OwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme3TWM2OD17Lk[5OlU{KM7:TR?= M2PvSXNCVkeHUh?=
HUTU-80 NYr3R4ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfpRVExUUN3ME25Mlc1PjR{IN88US=> NVvvVnFqW0GQR1XS
LS-411N NGTPZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHji[INKSzVyPUGwMlA2PjdizszN Mk\YV2FPT0WU
RPMI-8402 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e0TmlEPTB;MUCuNVE3KM7:TR?= M3XIZ3NCVkeHUh?=
KU812 NFzq[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzITWM2OD1zMD6yPVkyKM7:TR?= M3;WTHNCVkeHUh?=
EW-1 NWPHN4tZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHraTmVKSzVyPUGwMlQ1OjVizszN NXf1WXROW0GQR1XS
HC-1 NFHqdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z0PGlEPTB;MUCuOFg1PCEQvF2= MXXTRW5ITVJ?
NB69 NHPoW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnoVpZKSzVyPUGwMlUxPDNizszN NEPtOFRUSU6JRWK=
MFH-ino NEHv[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLD[|I3UUN3ME2xNE45OzB|IN88US=> MVXTRW5ITVJ?
CCRF-CEM NEn5W2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m5WmlEPTB;MUGuOVk4KM7:TR?= NWnK[JBDW0GQR1XS
SK-N-DZ NHLTNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm1[5dKSzVyPUGyMlA1OzZizszN NXrlUIQ3W0GQR1XS
NCI-H720 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF{LkG3NFUh|ryP NIHpc2hUSU6JRWK=
HCC1187 NFO0NWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzEWoV6UUN3ME2xNk4zODRzIN88US=> NWTFcWJ6W0GQR1XS
IST-SL2 MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjGVFdKSzVyPUGyMlQ5PzJizszN M1L3SXNCVkeHUh?=
KE-37 NF3udGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W4WWlEPTB;MUKuO|k3PiEQvF2= MX3TRW5ITVJ?
HCC1599 Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm2S5QxUUN3ME2xNk46ODZ7IN88US=> M1[xdXNCVkeHUh?=
A4-Fuk NUPWRYpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzMcmtKSzVyPUGyMlk2QDZizszN NGq4PGxUSU6JRWK=
NKM-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4SyUWlEPTB;MUOuNlkzPSEQvF2= MXHTRW5ITVJ?
BE-13 NYrTfGM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jJUGlEPTB;MUOuO|k5QSEQvF2= M2jWfHNCVkeHUh?=
MV-4-11 MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLBTWM2OD1zND6wN|I1KM7:TR?= NV;DZ5FvW0GQR1XS
OPM-2 MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\JcGE3UUN3ME2xOE41ODh3IN88US=> MlPvV2FPT0WU
KARPAS-422 NW\aOmZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF2LkWxNlYh|ryP NHLuTlBUSU6JRWK=
RPMI-8226 NXjzfXFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXaOVJKSzVyPUG0Mlg6OTVizszN MXrTRW5ITVJ?
KARPAS-45 M3WxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmKzTWM2OD1zNT63O|E3KM7:TR?= MUnTRW5ITVJ?
SK-PN-DW MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{juNGlEPTB;MUWuPFY{OSEQvF2= NWnWUmFnW0GQR1XS
LC-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnviTWM2OD1zNj6xOVA3KM7:TR?= Mn3XV2FPT0WU
NCI-H1648 NETIUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GzTWlEPTB;MU[uNlU1KM7:TR?= M4L6TnNCVkeHUh?=
RL95-2 NX7BOG9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF4LkO5O|gh|ryP MWTTRW5ITVJ?
KNS-42 M2XTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\m[WlEPTB;MU[uO|I4PCEQvF2= MUfTRW5ITVJ?
RPMI-6666 NWToRoFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvkXFhLUUN3ME2xOk46OjFzIN88US=> MXHTRW5ITVJ?
SIG-M5 NGe0O2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF5LkG5NFMh|ryP MWfTRW5ITVJ?
VA-ES-BJ NEDQWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LPTWlEPTB;MUeuO|Q2OSEQvF2= NHP2d5NUSU6JRWK=
MONO-MAC-6 NG\R[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2mzcWlEPTB;MUeuPVMyOiEQvF2= M4rGOnNCVkeHUh?=
LAN-6 NUm3[21IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u4cGlEPTB;MUiuO|U2PyEQvF2= NX3DUW96W0GQR1XS
A388 NVHWeo57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHpb4hKSzVyPUG5MlMxPTlizszN NFyxNodUSU6JRWK=
SK-NEP-1 MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJyLkKxN|Ih|ryP NFf5NlhUSU6JRWK=
TE-10 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWzOJJYUUN3ME2yNE42OjJzIN88US=> NYj5[FVuW0GQR1XS
HL-60 NYHTb3FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nVN2lEPTB;MkCuPVA6QSEQvF2= MoT2V2FPT0WU
MC116 NGXo[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2OxemlEPTB;MkGuO|IzOSEQvF2= NYPOUGV6W0GQR1XS
SW962 NVG0ToJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;K[IZKSzVyPUKxMlc6OTVizszN NWLQeGJOW0GQR1XS
NOMO-1 NH;lWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX0fG5KSzVyPUKyMlY2PjRizszN MnzFV2FPT0WU
CTB-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fufGlEPTB;MkKuPFY4OSEQvF2= MmjLV2FPT0WU
MRK-nu-1 NFLTT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ{LkmwO|Qh|ryP NH[3eo1USU6JRWK=
GR-ST MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfYTWM2OD1{Mz63OkDPxE1? MnHTV2FPT0WU
HH NYPTOIxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkntTWM2OD1{ND6wNFMh|ryP M{faZnNCVkeHUh?=
NCI-H1963 NXHIXGxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJ2LkC3PFIh|ryP MkC4V2FPT0WU
QIMR-WIL MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH4doNlUUN3ME2yOE45Pzd{IN88US=> NXPHfINwW0GQR1XS
CGTH-W-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ3LkC3NlMh|ryP NY\ScmROW0GQR1XS
LP-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XzNGlEPTB;MkWuOlU2OSEQvF2= MXPTRW5ITVJ?
NCI-H748 NEXIbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PZ[GlEPTB;Mk[uOVE{PyEQvF2= NEXtelRUSU6JRWK=
PF-382 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrjcGhKSzVyPUK3MlIzOjNizszN NI\WO4JUSU6JRWK=
ATN-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nlSWlEPTB;MkeuN|c{OiEQvF2= NGS5UW5USU6JRWK=
L-540 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULoW25KUUN3ME2yO{43PDV7IN88US=> NEfQNWJUSU6JRWK=
LXF-289 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ5Lke1NVkh|ryP M{m3UnNCVkeHUh?=
LS-513 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X5emlEPTB;MkiuNVgxPyEQvF2= M3G4N3NCVkeHUh?=
NCI-H1581 NY\4e3VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC2NnJKSzVyPUOwMlM6PzZizszN NVHtN4NUW0GQR1XS
ES6 NVKyO5JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTNyLk[4PVkh|ryP MkPUV2FPT0WU
SW982 M1foUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;1TWM2OD1|MD64OVY3KM7:TR?= NIC2S|JUSU6JRWK=
DOHH-2 M4jpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe4Z2kyUUN3ME2zNU42QDl|IN88US=> NHm1NpVUSU6JRWK=
DB NWLQXFlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SyTmlEPTB;M{OuPVQ{OSEQvF2= Mkj4V2FPT0WU
MPP-89 M1\Cd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHFNIV3UUN3ME2zOE4yPzV4IN88US=> NHi5bnpUSU6JRWK=
LB831-BLC NF\6c5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTN2LkWxPFQh|ryP MlmyV2FPT0WU
NB5 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlruTWM2OD1|ND64OVM2KM7:TR?= MWjTRW5ITVJ?
GB-1 NWPuToVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TwbGlEPTB;M{WuNFQ3QSEQvF2= MoLuV2FPT0WU
TE-15 NIXDVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPLN4xKSzVyPUO1MlIzOzhizszN MYTTRW5ITVJ?
LC4-1 MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDGcGdKSzVyPUO1MlM5PDdizszN MnzOV2FPT0WU
NCI-H747 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7kTWM2OD1|Nj6xN|Y6KM7:TR?= NXKyNpFvW0GQR1XS
NTERA-S-cl-D1 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn3dGwxUUN3ME2zPE44OzR5IN88US=> M2nodHNCVkeHUh?=
SK-MM-2 NIrkb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTRTWM2OD12MD6xNVQ3KM7:TR?= MmnWV2FPT0WU
TGW MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXuTWM2OD12MT6wOVY{KM7:TR?= MYTTRW5ITVJ?
ONS-76 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLRS5ZIUUN3ME20Nk41QDh|IN88US=> NGX3NJVUSU6JRWK=
CPC-N M{HIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPjdpdKSzVyPUSyMlk6PzFizszN MUjTRW5ITVJ?
ES4 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTR2LkSxOVMh|ryP NInmVZpUSU6JRWK=
Daudi MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXkPWZFUUN3ME20OU4xQDJ5IN88US=> MYLTRW5ITVJ?
MOLT-4 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW2TWM2OD12NT6wPFU{KM7:TR?= M2SwdnNCVkeHUh?=
HT-144 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6zc|ZKSzVyPUS2MlczPiEQvF2= Mn;yV2FPT0WU
SW872 NWnVXHZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LXUGlEPTB;NEiuNVk{OyEQvF2= NV;xXpNxW0GQR1XS
D-283MED NWD0NVZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf5bnZsUUN3ME20PE4{PTR{IN88US=> NX\MWpN2W0GQR1XS
NCI-H2126 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjOdHNKSzVyPUS4Mlg1PzZizszN NYHSfXBqW0GQR1XS
NCI-SNU-16 NULHWo1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfWTWM2OD12OT6yNVQ{KM7:TR?= NHfpc3FUSU6JRWK=
CESS M2iz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3wfG4yUUN3ME20PU42ODh6IN88US=> M1zD[nNCVkeHUh?=
A101D NYPyeoFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLaTWM2OD12OT65O|M3KM7:TR?= MVnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:[1]
+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:[1]
+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method: Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID